Olaptesed pegol not checked

TME Pharma AG · NOX-A12

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“400 mg per week as continous infusion until progression or intolerable toxicity”In the company’s words, NCT04901741 on ClinicalTrials.gov
Tested for
Metastatic Pancreatic Cancer, Glioblastoma
Main trialPhase 2
“The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel, to assess safety and tolerability and time-to-event endpoints.”In the company’s words, NCT04901741 on ClinicalTrials.gov
Other names
NOX-A12

Other drugs for Metastatic Pancreatic Cancer

All 203 drugs for Metastatic Pancreatic Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Mar 2028 Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
Phase 1/2Active, not recruiting Dec 2028 Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Olaptesed pegol

Following is part of Solo: you see every change to Olaptesed pegol the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in